- Email: [email protected]
Cumulative Chapter Titles Keyword Index, Vol. 1–22
CUMULATIVE C H A P T E R TITLES KEYWORD I N D E X , VOL.
1-22
365
a d e n y l a t e c y c l a s e , 6 , 233; 6 , 227; 12, 172; 2, 293 adenosine, neuromoduiator, 1 a d j u v a n t s , 9 , 244 a d r e n a l s t e r o i d o g e n e s i s , 2 , 263 B - a d r e n e r g i c b l o c k e r s , 10, 51; 2, 81 affinity labeling, 9, 2 E a l c o h o l consumption, d r u g s and d e t e r r e n c e , 4 , 246 a l d o s e r e d u c t a s e , 1 9 , 169 a l k a l o i d s , 1 , 3 1 1 ; 2 , 358; 322; 5 323; 6 , 274 a m i n o c y c l i t o i a n t i b i o t i c s , 12, 110 a n a l g e s i c s ( a n a l g e t i c ) , 1 , T O ; 2 , 33; 3, 36; 37;
2,
4,
4, 2, 31; 6 , 34; 7 , 31; 8 , 20; 9 , 11; lo, 12; 1 1 , 2 3 ; E , 20; 3, 4 1 ; 3, 31; E , - 3 2 ; lg, 41; 1 7 , 21; 18,5 1 ; 2,1 ; T O,21; 2 1 , 21 androgen a c t i o n , 21, 179 anesthetics, 1 , 30; 2, 24; 3 , 28; 4,28; 1,39; 8, 29, 10, 30 a n i m a l models, a n x i e t y , 15, 51 a n i m a l models, memory a n d l e a r n i n g , 12, 30 a n o r e x i g e n i c a g e n t s , 1,51; 2 , 4 4 ; 3 7 4 7 ; 5 , 40; 8, 42; 11,200; 15, 172 a n t a g o n i s t s , c a l c i u m , 1 6 , 257; 3, 7 1 ; fi,-79 a n t a g o n i s t s , GABA, 1 3 , T l ; 15, 4 1 ; a n t a g o n i s t s , n a r c o t i c 7 , 3 F 8,20; 9 , 11; 1 0 , 12; 1 1 , 23 antagonists, non-steroidal, 1 , 191 ; 35 184 4 , 199 a n t a g o n i s t s , s t e r o i d a l , 1,273; 2 , 258; 3 , 207; anthracycline antibiotics, 1 4 , 288 a n t i a g i n g d r u g s , 2, 214 antiallergy agents, 1 , 92; 2 , 83; 3 , 84; 7 , 89; 9 , 85; 2, 85; lo, 80; 1 1 , 51; 11,70; 9 , - 5 1 ; f i Y 5 1 ; 15, 59; 177 51; 6 1 ; 3,93; 20, 71; 21, 73; 22, 73 antianginah, 1 , 78; 2, 69, 3, 71; 5 , 63; 1, 69; 8, 63; 2, 67; 12, 39; 17, 71 antianxiety agents, 1 , 1; 2, 1 ; 3 , 1 ; 4 , 1 ; 5 , 1 ; 6 , 1 ; 7, 6; 8 , 1; 9 , 1; 1 0 , 2; 11, 1312, l o ; 13, 21; 2, 22;-15, - 22; 16,-3i; 17, 1 1 ;
Is,
78, 11;
2,1 1 ;
20, 1 ;
11, 1 1 ; c ,
11
2,
6 , 80; 8 , 63; 2, 67; 12, 39; 99; 2, 95 antzrrhythmics, 1785; 5 , 87; 6, 108; a n t i b a c t e r i a l agen'ts, 1 , 118; 2 , 112; 3 , 105; 4 , 108; 17, 107; 18, 109; 19; 107; z y 145,1557 2 , 139antibiotics, 1 , 1 0 9 7 2 , 102; 3, 93; 4 , 8 8 ; 5 , 75; 5 , 156; 6, 99; 7 , 99; 7 , 217; 8 , T04; 9 , 93; 2, 139, 2467 1 1 , 87; 2, 2 7 1 ; 12, 101,115; 2 , 103, 149; 1 4 , 107; 1 5 , 106; 17, 107; 18, 109; 21, 131 a n t i b o d i e s , d r u g c a r r i e r s and t o x i c i t y reversal, 3, 233 a n t i b o d i e s , monoclonal, 243 a n t i c o n v u l s a n t s , 1, 30; 2, 24; 3 , 28; 28; 1, 39; 8 , 29; 10, 30; 11, 13; 12, 10; 13, 21; 2 ; 22; l?, 22; 31; 3,11; 1 1 ; 2 , 11;
16,
20,
11; 21,
11
antzepresszts,
11; 1 1 , 3; 12, 21
4,
16,
1 , 12; 2 , 1 1 ; 3, 1; 13, l;-fi, 1;
14; 4 ,
lx, 5,1 ; -
18,
13; 2 , 13; 6, 15; 1, 18; 8 , 1; 1 7 , 41; 18, 4 1 ; 20, 31; 22,
6 , 192 a n t i d i a b e t i c s , 1 , 1 6 4 ; 2 , 176; 3 , 156; 4 , 1 6 4 ; antifungals, 2, 157; ;2 145; 6, 138; 3 , 129; 6 , 129; 1, 109; 8, 116; 9 , 107-, -910 1 2 0 ; 11, 101; 13,-113; 15, 139; 17, 139; 2,127; 22, 159 antTg1aucoma a g e n t s , 20, 83 a n t i h y p e r l i p i d e m i c s , 2 , 162; 18, 161 antihypertensives, 1, 59; 2, 48; 3 , 53; 47; 5 , 49; 6 , 52; 1, 59; 8 , 52; 2, 57; 1 1 , 61; 3, 60; 13, 71; 1 4 , 61; 2 , 797 73; -
5,
61; 18, 69; 1 9 , 6 1 ; 21, 63;
22,
la,
6 3
a n t i i n f z m m a t o r z s , non-steroidal, 1 , 224; 2 , 217; 3 , 215; 4 , 207; 10, 177; 13, 167; 1 6 , 189 225; 6 , 182; 7 , 208; 8 , 214; 9 , 197; a n t i - i s c h e m i c a g e n t s , 177 71 a n t i m e t a b o l i t e c o n c e p t T d r u g d e s i g n , 11,223
-
c, 5,
366
CUMULATIVE CHAPTER T I T L E S KEYWORD I N D E X , VOL.
-
1-22
antimicrobial drugs c l i n i c a l problems and o p p o r t u n i t i e s , 21, 119 a n t i n e o p l a s t i c s , 2, 166; 3, 150; 4, 154; 5, 144; 129; 128; 2, 139; 10, 131; 118; 12, 120; 13, i20; 14,132; 15, 130; 16, 137; 163; -
2,
1,
8,
z,163; z,137 1%; I , 150; 2, 131; 2, 147; 3, 126; 3 ,
18, 129; 19, 137;
antGarasitiG,
17,
1, 140; 4, 126; 5, 116; 7, 145; 8, 1417 9 , 115; 3, 156; 11, 121;12, 140; 13,-130;
14,72;-15, 1207 16,125; 17, 129; 19, 147 6, 4279, 19 2; 1 ; 3, 1 ; 4, 1 ; 5 , 1 ; 6, 1 ; 7, 6; 8, 1 ; 9, 1 ; 10, 2; 11, 3; 2, 1 ; 13, IT; 14,-12; 3 , 12; 16, - 11; 18, 21; 197 21;
a n t G a r k i n s o z s m drugs, antipsychotics, 1, 1 ;
21, 1 ;
22, 1
a n t i r a d i a t i o n a g e n t s , 1 , 324; 2, 330; 2, 327; 5, 346 a n t i r h e u m a t i c d r u g s , 18, 171 antithrombotics, 7, 7 c 8, 73; 9, 75; 99; 12, 80; 14, 71; 17, 79 1T8; a n t i v i r a l a g e n t s , 1 , 1297 2, 122; 3, 116; 4, 117; 5, 10, 167; 1 1 , 128; 3,-139; 15, 149; 16, 149; 7, 119; 8, 150;-9, 128; -
to,
1m;6,
13,139;ig, ii7;-g, 147
a p o z h i n e c h e m i s t r y , 4, 331 a r a c h i d o n a t e l i p o x y g e n z s e , 16, 21 3 arachidonic acid cascade, 182; 14, 178 a r a c h i d o n i c a c i d m e t a b o l i t e r 17, 203a r t h r i t i s , 13, 167; 16, 189; 175; 171; 201 asymmetric s y n t h e s i s , 13, 282atherosclerosis, 1 , 178; 2, 187; 2, 172; 178; 5, 180; 6, 150;
1 z
v,
3,
11,
4,
169; 8, 183; 15,-162, 3,-161; 11,189 atrial n a t r i u r e t z factor, 21, 273 a u t o r e c e p t o r s , 19, 51 b a c t e r i a l r e s i s t a n c e , 13, 239; 3, 119
1,
bacterial toxins, 12, 2 1 1 basophil d e g r a n u l a t z n , biochemistry, 18, 247 behavior, serotonin, 47 benzodiazepine r e c e p t o r s , 21 b i o i s o s t e r i s m , 2, 283 b i o l o g i c a l f a c t o r s , 2, 39; 1 1 , 42 b i o l o g i c a l membranes, 1 1 , 2 2 2 b i o p h a r m a c e u t i c s , 1,3 3 ; 2, 340; 3 , 337; 302; 5 , 313; 6, 264; 7, 259;
1,
5,
2,
8, 332
b i o g y n t h e s i s , a n t i b i o t i c s , 12, 130 b l o o d - b r a i n b a r r i e r , 20, 305blood enzymes, 1, 2 3 7 b o n e , m e t a b o l i c disease, 12, 223; 15, 228; 17, 261; 22, 169 calcium antagonists/modulaGrs, 17771; g,’;T9; 85 16,257; 18,203 calmodulin a n t a g o n i s t s , SAR, cancer therapy, 2, 166; 3, 1%; 4, 154; 5 , 144; 7, 129; 8, 128; 2, 139;
”,
11,
13, ,120;14,-132; 15; 130; 16, 137; 151; 3, 131; 115;12, 120; 17, 163; 18, 129; 21, 257 c a n z b i n o i d s r 9, 253c a r b o x y l i c acid; m e t a l a t e d , 2, 278 c a r c i n o g e n i c i t y , c h e m i c a l s , 12, 234 c a r d i o t o n i c a g e n t s , 16,93; 5, 92; 2, 71 c a r d i o v a s c u l a r a g e n t s , 2, 6 T c a t a l y s i s , i n t r a m o l e c u l a r , 1,279 c e l l i n v a s i o n , 2, 229 c e l l m e t a b o l i s m , 1,267 c e l l m e t a b o l i s m , c y c l i c AMP, 2, 286 c e l l u l a r r e s p o n s e s , i n f l a m m a t o r y , 12, 152 c h e m o t a x i s , 15, 224; 17, 139; 17, s 3 c h o l e c y s t o k i n z , 18, chronopharmacology, 11,25 1 9,
CUMULATIVE CHAPTER TITLES KEYWORD I N D E X , VOL. 1-22
367 -
11,
c o g n i t i v e d i s o r d e r s , 19, 31; 31 c o l l a g e n a s e s , 1 9 , 231c o l o n y s t i m u l a t i n g f a c t o r , 21, 263 complement i n h i b i t o r s , 15, 193 complement s y s t e m , 7 , 2 X c o n f o r m a t i o n , n u c l e o s i d e , b i o l o g i c a l a c t i v i t y , 5 , 272 conformation, p e p t i d e , b i o l o g i c a l a c t i v i t y , 3 , 2 2 7 c o n g e s t i v e h e a r t f a i l u r e , 22, 85 c o t r a n s m i t t e r s , 0, 51 c y c l i c AMP, 2, 286; 6 , 215; 8 , 224; 1 1 , 291 c y c l i c GMP, 1 1 , 291 c y c l i c n u c l e o t i d e s , 9 , 203; 10, 192; 15, 182 cyt ochrome P-450, 9 ,-290; 19,201 DDT-type i n s e c t i c i d e s , 9 , 3 0 d e r m a t o l o g y and d e r m a t o l o g i c a l a g e n t s , 12, 162; 18, 181; 22, 201 d i a b e t e s , 9, 182; 11, 170; 3, 2,769; 22,213 D i e l s - A l d e r r e a c t i o n , i n t r a m o l e c u l a r , 9 , 270 diuretic, 1, 67; -2 , 59; -3 , 62; -6 , 8 6 83; 10, 71; 1 1 , 71; 61; 15, 100 D N A F s e q u e n c e - s p e c i f i c d r u g s , 2 2 , 259 1 4 , 12; 1 5 , 7 2 ; 1 6 , 1 1 , 103; 18, 21; 0, 4 1 ; 22, 107 dopamine, 13, 1 1 ; d r u g a b u s e , CNS a g e n t s , 9,38 d r u g a l l e r g y , 2, 240 d r u g c a r r i e r s , a n t i b o d i e s , 15, 233 drug carriers, liposomes, 1 q 250 drug d e l i v e r y systems, 1 5 , 3 0 2 ; 275; 305 drug discovery, n a t u r a l s o u r c e s , 301 d r u g d i s p o s i t i o n , 15, 277 d r u g m e t a b o l i s m , 2,227; 4 , 259; 5 , 246; 6 , 205; 8, 234; 9 , 290; 304;-14, - 188; 5, 319; 17, 373 190; 12, 201; 13, 196; e l d e r l y , d r u g a c t i o n i n , 20, 295 electrosynthesis, 30F e n a n t i o s e l e c t i v i t y , drug metabolism, 13, 304 endorphins, 41; 31; 3, 32; 1 c 4 1 ; 1 7 , 21; 18, 51 15, 207e n z y m a t i c monooxygenation r e a c t i o n s , 7 , 249; 9 , 234; f i F 2 4 9 enzyme i n h i b i t o r s , enzyme immunoassay , 18, 285enzymes, b l o o d , 1 , 2'55 enzymes, p r o t e o l y t i c i n h i b i t i o n , 13, 261 enzyme s t r u c t u r e - f u n c t i o n , 22, 293enzymi c s y n t h e s i s , 19, 263e x c i t a t o r y amino a c i G , 22, 31 f e r t i l i t y c o n t r o l , 10,n o ; 1 4 , 168; 21, 169 f o r s k o l i n , 19, 293 free r a d i c a l p a t h o l o g y , 10, 257; 22, 253 GABA, a n t a g o n i s t s , 13, 3 E 41gamete b i o l o g y , f e r t i l i t y c o n t r o l , 10, 240 1 , 99; ,2 9 1 ; 4 , 56; 6 , 68; 8 , 93; 10, 90, gastrointestinal agents, 3,89; 0, 117 1 6 , 83; 1 7 , 89; 12, 91; genetherapy, 8, 2 E g l u c a g o n , mechanism, '8, 193 glucocorticosteroids, 13, 179 g l y c o s y l a t i o n , non-enzymatic, 261 growt h f a c t o r , 11, 159 g r o w t h hormone, 20, 185 h a l l u c i n o g e n s , 1 , 12; 2 , 11; 3 , 1 4 ; 4 , 13; 5 , 23; 6 , 24 15, 8 9 ; c , - 7 1 h e a r t d i s e a s e , ischemic: h e a r t f a i l u r e , 13, 92; 5 7 9 3 ; 22, 85 h e m o r h e o l o g i c agents, 3, 99
159;
S,
2, 17,
9,
0,
11,
3,
12, 13, 3,
s,
2,
368 -
CUMULATIVE CHAPTER TITLES KEYWORD INDEX, VOL. 1-22
h e r b i c i d e s , 2, 311 heterocyclic chemistry, 278 hormones, g l y c o p r o t e i n , 211 hormones, n o n - s t e r o i d a l , 1 , 191; 3 , 184 1 1 , 158; 1 6 , 199 hormones, p e p t i d e , 5 , 210; 7 , 194; 8 , 204; 10, 2 0 2 ; hormones, s t e r o i d , 1 , 213; 208, 3, 207, 199 18, 149 h o s t m o d u l a t i o n , i n f e c t i o n , 8 , 160;-14,46; 5 - h y d r o x y t r y p t a m i n e , 2, 273;-7, 47; 41 hypersensitivity, delayed, 8,-284 h y p e r s e n s i t i v i t y , i m m e d i a t e , 7 , 238; 8, 273 h y p e r t e n s i o n , e t i o l o g y , 9 , 50h y p n o t i c s , 1 , 30; 2, 24;-3, 28; 4 , 28; 7 , 39; 8 , 29; 1 0 , 30; 11, 13; 1 2 , 10; 13, 21; 22;-15, - 227 16, 3 i ; 17, i i ; fi,-ii; ig,Ti; 22, 11 I g E T 18, 2 f i 18, 265 immunity, c e l l u l a r m e d i a t e d , 17, 91; immunoassay, enzyme, 18, 285 immunostimulants, a r t h r i t i s , 2,38; 1 4 , 146 immunosuppressives, a r t h r i t i s , 11 138immunotherapy, cancer, 9, 151 18, 149; 22, 127 immunotherapy , i n f e c t i o u s d i s e a s e s 14,t 14 i n f e c t i o n s , s e x u a l l v t r a n s m i t t e d .' -' i n f l a m m a t i o n , 22, 245 i n h i b i t o r s , complement, 2, 193 i n h i b i t o r s , c o n n e c t i v e t i s s u e , _II, 175 i n h i b i t o r s , enzyme, 13, 249 i n h i b i t o r s , i r r e v e r s i b l e , 9 , 234; 16, 289 i n h i b i t o r s , p l a t e l e t a g g r e g a t i o n , 6 , 60 i n h i b i t o r s , p r o t e o l y t i c enzyme, 13, 261 inhibitors, renin-angiotensin, 82 i n h i b i t o r s , r e v e r s e t r a n s c r i p t i o n , 8 , 251 i n h i b i t o r s , t r a n s i t i o n s t a t e analogs, 7 , 249 inorganic chemistry, medicinal, 8 , 294i n s e c t i c i d e s , 2, 300; 17,311 i n s u l i n , mechanism, 18, 193 i n t e r f e r o n , 8, 150; E,211; 1 6 , 229; 17, 151 interleukin-1, 2 0 , 1 7 z 2, 235i n t e r l e u k i n - 2 , 2 , 191 i n t e r o c e p t i v e d i s c r i m i n a t i v e s t i m u l i , a n i m a l model o f a n x i e t y , 2, 51 intramolecular c a t a l y s i s , 1, 279 i o n o p h o r e s , monocarboxylic a c i d , 3, 246 i r o n c h e l a t i o n t h e r a p y , 13, 219 i s o t o p e s , s t a b l e , 2, 3 1 E 2 , 173 6 - l a c t a m a n t i b i o t i c s , 1 1 , 271; 12, 101; 13, 149; 20, 127,137 B-lactamases, 13, 239;?7, 119 l e a r n i n g , 3 , 2m; 571 l e u k o c y t e m o t i l i t y , 17, 181 l e u k o t r i e n e s , 17,2 9 F 1 9 , 241
2, 12,
z,
z,
2,
I_x
16,
LHRH,
0, 203
l i p i d metabolism, 9 , 172; lo, 182; 1 1 , 180; 12, 191; 13, 184; 1 4 , 198; 15, 162 l i p o s o m e s , 3, 250 lipoxygenase, 16, 213; 1 7 , 203 l y m p h o c y t e s , d e l a y e d h y p e r s e n s i t i v i t y , 8 , 284 m a g n e t i c r e s o n a n c e , d r u g b i n d i n g , 1 1 , 377 market i n t r o d u c t i o n s , 1 9 , 313, 20,?15; 21, 323; 22, 315 mast c e l l degranulationTbiochemGtry, 247 -
lc
mechanism, d r u g a l l e r g y , 3 , 240 mechanisms o f a n t i b i o t i c r e s i s t a n c e , membrane f u n c t i o n , lo, 317
1,217; '3, 239; 17,119
CUMULATIVE C H A P T E R T I T L E S KEYWORD I N D E X , VOL.
1-22
369
membrane r e g u l a t o r s , 11,210 membranes, a c t i v e t r a n s p o r t , 11, 222 memory, 3, 279; 2, 30; 16, 5 1 m e t a b o l i s m , c e l l , 1,2 6 7 y 2 , 286 m e t a b o l i s m , d r u g , 3, 227; 6, 259; 5, 246; 6, 205; 8, 234; 9, 290; 11, 190; 12, 201T 13, 195; 3,354; 14, 788 metabolism, l i p i d , 1 97 ,2; 10, 182; 111 ,80; 12, 191; 14, 198 m e t a b o l i s m , m i n e r a l , 12, 227metal c a r b o n y l s , 8, 3 B metals, d i s e a s e , 2, 321 m i c r o b i a l p r o d u c t s s c r e e n i n g , 11, 149 m i g r a i n e , 2, 41 m i t o g e n i c f a c t o r s , 2, 237 m o l e c u l a r m o d e l i n g , 3, 269 m o n o c l o n a l a n t i b o d i e s , 16, 243 monoxygenases, c y t o c h r o m F P - 4 5 0 , 9 , 290 m u s c l e r e l a x a n t s , 1,30; 2, 24; 2 ; 28; -4, 28; -8, 37 m u s c u l a r d i s o r d e r s , 12, 260 m u t a g e n i c i t y , mutagens, 12, 234 m u t a g e n e s i s , S A R of p r o t e i n s , 18, 237 n a r c o t i c a n t a g o n i s t s , 7, 31; g F 2 0 ; 2, 11; lo, 12; 11, 23; 13, 41 n a t r i u r e t i c a g e n t s , 19; 253 n a t u r a l p r o d u c t s , 6 , 2 7 4 ; 15, 255; 17,301 n a t u r a l k i l l e r c e l l s , 18, x 5 n e o p l a s i a , 8, 160; 1 0 , 1 4 2 n e u r o p e p t i d e s , 21, q; 2, 51 neurotensin, 17731 n e u r o t r a n s m i t t e r s , 3, 264; 4 , 270; 12, 249; 14, 42; 19, 303 n i c o t i n i c a c e t y l c h o l T n e r e c e p t o r , 228,1 ,NMR i n b i o l o g i c a l s y s t e m s , 20, 267NMR i m a g i n g , 20, 277 non-enzymatic g l y c o s y l a t i o n , 14, 261 non-nutritive, sweeteners, x 7 3 2 3 non-steroidal antinflammatories, 1, 224; 2, 217; 3, 215; 4 , 207; 5, 225; 6, 182; 7, 208; 8, 214; 9, 1 9 3 ; - E , 172;s, 167; 16,183 n u c i e i c acid-drug i n t e r a c t i < n s , 13, 316 n u c l e i c a c i d , s e q u e n c i n g , 16, 2 9 F n u c l e i c acid, s y n t h e s i s , 1 s ; 299 n u c l e o s i d e c o n f o r m a t i o n , 5, 272 n u c l e o s i d e s , 1, 299; 2, 304; 3, 297; 5 , 333 n u c l e o t i d e m e t g b o l i s m , 21, 2 4 7 n u c l e o t i d e s , 1, 299; 2 , 7 0 4 ; 3, 297; 5 , 333 n u c l e o t i d e s , c y c l i c , 9 , 203; 70, 192; 15, 182 o b e s i t y , 1,51; 2, 4 4 7 3, 47;-5, 40; 8 7 4 2 ; 11,200; 15, 172; 19, 157 o n c o g e n e s , 18, 275; 21 ,-159,237 o p i o i d r e c e p G r , 1 1 , 3 3 ; 12, 20; 13, 41; 3, 31; 15, 32; '6, 41; 17, 21; 18, 51; 20, 2 1 ; 2 1 , 21 o p i x d s , 1 2 7 2 0 ; 1 6 7 4 1 ; 17, 21; 2, 51; 20, 21; 21, 21 o r g a n o c o p p e r reagents, 327 o s t e o a r t h r i t i s , 22, 179 osteoporosis, z T 1 6 9 p a r a s i t e b i o c h e m i s t r y , 16, 269 p a t e n t s i n m e d i c i n a l c h e m i s t r y , 2, 331 p a t h o p h y s i o l o g y , plasma membrane, 10, 213 p e n i c i l l i n b i n d i n g p r o t e i n s , 18, 1p e p t i c u l c e r , 1, 99; 2, 91; 4 7 5 6 ; 6, 68; 8, 93; 10, 90; 12, 91; 16, 83; 17, 89; 18, 89; 3, 81; g y 93; 2 , 191 peptide conformation, 13, 227
LE
37 0 -
CUMULATIVE C H A P T E R TITLES KEYWORD I N D E X , VOL.
1-22
p e p t i d e hormones, 5 , 210; 7, 194; 8 , 204; 10, 202; 1 1 , 158; 303 7 , 194; 8 , 204; 10,702; 1 6 , 199 p e p t i d e , hypothalamus, p e p t i d e , S A R , 5 , 266 p e p t i d e , s y n t h e s i s , 5 , 307; 7 , 289; 309 peptide, synthetic, 289; 2, 296 p e p t i d e , t h y r o t r o p i n , 17, 31p e r i o d o n t a l d i s e a s e , 1% 228 pharmaceutics, 1 , 3 3 1 72 , 340; 3 , 337; 302; 5 , 313; 254; 264; 7 , 259; 33F p h a r m a c o k i n e t i c s , 3, 227; 3 , 337; 4 , 259; 4 , 302; 5 , 246; 5 , 313; 6 205; 8 , 234; 2, 290; 1 1 , 190;-12, - 2017 1 3 , 195; 13, 354; 1 4 , 788; 14,-309;
2,
16,
1,
2,
i,
1 6 , 319; 17, 333pharmacophorcidentification ,
6,
6,
15 , 267 pharmacophoric p a t t e r n s e a r c h i n g , 299 p h o s p h o l i p a s e s , 1 9 , 213; 22, 223 p h y s i c o c h e m i c a l p a r a m e t e r s , d r u g d e s i g n , 3 , 348; 4 , 314; 5 , 285 p i t u i t a r y hormones, 7 , 194; 8 , 204; 10, 252 plasma membrane p a t h o p h y s i o l o g y , 10 , 2 1 3 plasminogen a c t i v a t o r , 18, 257; 107 p l a t e l e t a c t i v a t i n g fact& ( P A F ) , 243; 20, 193 p l a t e l e t aggregation, 60 p o l y e t h e r a n t i b i o t i c s , 10, 246 polyamine m e t a b o l i s m , l r 253 p o l y m e r i c reagents, 11,281 p r o d r u g s , lo, 306; 2 x 303 p r o l a c t i n s e c r e t i o n , 15, 202 prostacyclin, 178p r o s t a g l a n d i n s , 3, 290; 5 , 170; 6 , 137; 7 , 157; 8 , 172; 9 , 162; 1 1 , 80 p r o t e i n growth f a c t o r s , 219 p r o t e i n a s e s , a r t h r i t i s , 1 4 , 219 protein kinases, 18, 213p r o t e i n k i n a s e C , 20, 227 psoriasis, 12, 1 6 F p s y c h i a t r i c E s o r d e r s , 11 , 42 p s y c h o s e s , b i o l o g i c a l f a x o r s , 2, 39 p s y c h o t o m i m e t i c a g e n t s , 9 , 27 pulmonary a g e n t s , 1 , 92,-2, 83; 3 , 84; 4 , 67; 5 , 55; 7 , 89; 9 , 85; 1 0 , 80; 51; 7 0 ; - 3 , 517 14, 5 i ; 15, 59; 17, 51; 18, 6 1 ; 2 0 , 71; 1_1, 73; 22, 73 q u a n t i t a t i v e S A R , 6 , 245; 8 , 313; 1 1 , 301; 3,292; 281 q u i n o l o n e a n t i b a c t e r i a l s , 2i, 139; 117 radioimmunoassays, 10, 284r a d i o i s o t o p e l a b e l e d d r u g s , 7 , 296 radioimaging agents , 293r a d i o l i g a n d b i n d i n g , 19, 283 receptor binding, 1 2 , 7 4 9 r e c e p t o r mapping, 1 4 , 299; 267 r e c e p t o r , c o n c e p t a Z f u n c t i o n , 21, 211 r e c e p t o r s , a d a p t i v e c h a n g e s , 19,241 r e c e p t o r s , a d r e n e r g i c , 15 , 2 1 T receptors, 6-adrenergic m o c k e r s , 1 4 , 81 1 6 , 21 r e c e p t o r s , benzodiazepine, receptors, cell surface, 127211 r e c e p t o r s , d r u g , 1 , 236; 2, 227, 8, 262 r e c e p t o r s , h i s t a m i n e , 14,-91 r e c e p t o r s , n e u r o t r a n s m i t t e r s , 3, 264 ; 12 , 249 r e c e p t o r s , n e u r o l e p t i c , 1 2 , 249 receptors, opioid, 3xg, 20; 13, 4 1 ; 1 4 , 31; 15, 32; 16, 4 1 ; 17, 21
2,
cc n,
6,
2,
c,
2,
z,
z,
la,
5,
11,
17,
CUMULATIVE C H A P T E R T I T L E S KEYWORD I N D E X , VOL.
1-22
recombinant DNA, 17, 229; 2, 307; 1 9 , 223 r e n a l blood f l o w , 1 6 , 103 r e n i n , 13, 8 2 ; 2 0 , 2 5 7 r e p e r f u s i o n i n j u r y , 22, 253 reproduction, 1, 2 0 5 2, 199; 3, 200; 4 , 189 r e v e r s e t r a n s c r i p t i o n , 8 , 251 rheumatoid a r t h r i t i s , l i , 138; 219; 171; 21, 201 SAR, q u a n t i t a t i v e , 6 , 4 5 ; 8 , 313; 1 1 , 301; 13, 292; 17, 291 s e d a t i v e - h y p n o t i c s , 7 , 39; 8, 29; lr 13; 12,lO; 13,Tl; 1 4 , 22; 15, 22; 1 6 , 31; 17, 1 1 ; 2 7 1 1 ; 1 1 ; E ,1 1 sedatives, 1 , 30; 2 , 24; 3 , 28; 28; 7 , 39; 8 , 29; 10, 30; 11, 13; 12, 10; 3 ; 21; fl, 22; 13, 22; T6, 31; 17, 11; 1 1 ; 20 , 1; 21, 1 1 s e r x o n i n , b e h a v i o r , 2 , 2 7 5 1,47serum l i p o p r o t e i n s , r e & l a t i o n , 12, 184 sexually-transmitted infections, 1 4 , 114 s i l i c o n , i n b i o l o g y and m e d i c i n e , lo, 265 s i c k l e c e l l anemia, 111, 247 s k e l e t a l muscle r e l a x a n t s , 8 , 37 s l o w - r e a c t i n g s u b s t a n c e s , 15, 6 9 ; 1 6 , 213; 17, 203; 17, 291 sodium/calcium e x c h a n g e , s 7 2 15 s o l i d s t a t e o r g a n i c c h e m i s t r y , 20, 287 s o l u t e a c t i v e t r a n s p o r t , 1 1 , 272 s o m a t o s t a t i n , 1 4 , 209; 18,199 SRS, 15, 69; l q 213; _?_;TT 203; 291 steroirhormon;, 1 , 213; 2 , 208; 3 , 207; 4 , 199 s t r o i d o g e n e s i s , a d r e n a l , 2 7 263 s t e r o i d s , 1, 312; 3 , 307;-4,- 281; 5 , 296; 5 , 192; 6, 162; 7 , 182; 8 , 194;
14,
18,
s,
18,
c,
1 1 , 192
s t i m u l a n t s , 1 , 12; 2 , 1 1 ; 3, 1 4 ; 4 , 13; 5, 13; 6 , 15; 7 , 18; 8, 11 2, 109 s t r o k e , p h a r m a c o l o g i c a l approaches; s u b s t a n c e P , 17, 271; 31 s u b s t i t u e n t c o n s t a n t s , 2 , 347 s u i c i d e enzyme i n h i b i t o r s , 16, 289 s u p e r o x i d e d i s m u t a s e s , 10, z 7 superoxide radical, 1 0 , 2 5 7 sweeteners, n o n - n u t r i E v e , 1 7 , 323 s y n t h e s i s , asymmetric , 9, 2 E s y n t h e s i s , computer-assisted, 12, 288; 16, 281; 21, 203 tandem mass s p e c t r o m e t r y , 2, 3 3 t h r o m b o s i s , 5 , 237 thromboxane s y n t h e t a s e , 22, 95 thromboxanes, 1 4 , 178 t h y r o t r o p i n r e l e a s i n g hormone, 2, 31 t o p o i s o m e r a s e , 21, 247 t o x i c i t y r e v e r s a c 15, 233 t o x i c i t y , m a t h e m a t i c a l models, 18, 303 toxicology, comparative, 11, 2 4 2 t o x i n s , b a c t e r i a l , 2, 2 1 F t r a n s c r i p t i o n , r e v e r s e , 8, 251 tumor n e c r o s i s f a c t o r , 227 235 vasoconstrictors, 4, 7 T vasodilators, 77; 2, 49 veterinary drugs, 161 v i r u s e s , 2, 238 v i t a m i n D , 10, 295; 15, 288; 17,261; 1 9 , 179 waking f u n c t G n s , S F 2 1 water, s t r u c t u r e s , 5 , 256 x e n o b i o t i c s , c y c l i c Z u c l e o t i d e m e t a b o l i s m , 2,182 x-ray c r y s t a l l o g r a p h y , 2, 293
18,
4,
16,
1-22
365
a d e n y l a t e c y c l a s e , 6 , 233; 6 , 227; 12, 172; 2, 293 adenosine, neuromoduiator, 1 a d j u v a n t s , 9 , 244 a d r e n a l s t e r o i d o g e n e s i s , 2 , 263 B - a d r e n e r g i c b l o c k e r s , 10, 51; 2, 81 affinity labeling, 9, 2 E a l c o h o l consumption, d r u g s and d e t e r r e n c e , 4 , 246 a l d o s e r e d u c t a s e , 1 9 , 169 a l k a l o i d s , 1 , 3 1 1 ; 2 , 358; 322; 5 323; 6 , 274 a m i n o c y c l i t o i a n t i b i o t i c s , 12, 110 a n a l g e s i c s ( a n a l g e t i c ) , 1 , T O ; 2 , 33; 3, 36; 37;
2,
4,
4, 2, 31; 6 , 34; 7 , 31; 8 , 20; 9 , 11; lo, 12; 1 1 , 2 3 ; E , 20; 3, 4 1 ; 3, 31; E , - 3 2 ; lg, 41; 1 7 , 21; 18,5 1 ; 2,1 ; T O,21; 2 1 , 21 androgen a c t i o n , 21, 179 anesthetics, 1 , 30; 2, 24; 3 , 28; 4,28; 1,39; 8, 29, 10, 30 a n i m a l models, a n x i e t y , 15, 51 a n i m a l models, memory a n d l e a r n i n g , 12, 30 a n o r e x i g e n i c a g e n t s , 1,51; 2 , 4 4 ; 3 7 4 7 ; 5 , 40; 8, 42; 11,200; 15, 172 a n t a g o n i s t s , c a l c i u m , 1 6 , 257; 3, 7 1 ; fi,-79 a n t a g o n i s t s , GABA, 1 3 , T l ; 15, 4 1 ; a n t a g o n i s t s , n a r c o t i c 7 , 3 F 8,20; 9 , 11; 1 0 , 12; 1 1 , 23 antagonists, non-steroidal, 1 , 191 ; 35 184 4 , 199 a n t a g o n i s t s , s t e r o i d a l , 1,273; 2 , 258; 3 , 207; anthracycline antibiotics, 1 4 , 288 a n t i a g i n g d r u g s , 2, 214 antiallergy agents, 1 , 92; 2 , 83; 3 , 84; 7 , 89; 9 , 85; 2, 85; lo, 80; 1 1 , 51; 11,70; 9 , - 5 1 ; f i Y 5 1 ; 15, 59; 177 51; 6 1 ; 3,93; 20, 71; 21, 73; 22, 73 antianginah, 1 , 78; 2, 69, 3, 71; 5 , 63; 1, 69; 8, 63; 2, 67; 12, 39; 17, 71 antianxiety agents, 1 , 1; 2, 1 ; 3 , 1 ; 4 , 1 ; 5 , 1 ; 6 , 1 ; 7, 6; 8 , 1; 9 , 1; 1 0 , 2; 11, 1312, l o ; 13, 21; 2, 22;-15, - 22; 16,-3i; 17, 1 1 ;
Is,
78, 11;
2,1 1 ;
20, 1 ;
11, 1 1 ; c ,
11
2,
6 , 80; 8 , 63; 2, 67; 12, 39; 99; 2, 95 antzrrhythmics, 1785; 5 , 87; 6, 108; a n t i b a c t e r i a l agen'ts, 1 , 118; 2 , 112; 3 , 105; 4 , 108; 17, 107; 18, 109; 19; 107; z y 145,1557 2 , 139antibiotics, 1 , 1 0 9 7 2 , 102; 3, 93; 4 , 8 8 ; 5 , 75; 5 , 156; 6, 99; 7 , 99; 7 , 217; 8 , T04; 9 , 93; 2, 139, 2467 1 1 , 87; 2, 2 7 1 ; 12, 101,115; 2 , 103, 149; 1 4 , 107; 1 5 , 106; 17, 107; 18, 109; 21, 131 a n t i b o d i e s , d r u g c a r r i e r s and t o x i c i t y reversal, 3, 233 a n t i b o d i e s , monoclonal, 243 a n t i c o n v u l s a n t s , 1, 30; 2, 24; 3 , 28; 28; 1, 39; 8 , 29; 10, 30; 11, 13; 12, 10; 13, 21; 2 ; 22; l?, 22; 31; 3,11; 1 1 ; 2 , 11;
16,
20,
11; 21,
11
antzepresszts,
11; 1 1 , 3; 12, 21
4,
16,
1 , 12; 2 , 1 1 ; 3, 1; 13, l;-fi, 1;
14; 4 ,
lx, 5,1 ; -
18,
13; 2 , 13; 6, 15; 1, 18; 8 , 1; 1 7 , 41; 18, 4 1 ; 20, 31; 22,
6 , 192 a n t i d i a b e t i c s , 1 , 1 6 4 ; 2 , 176; 3 , 156; 4 , 1 6 4 ; antifungals, 2, 157; ;2 145; 6, 138; 3 , 129; 6 , 129; 1, 109; 8, 116; 9 , 107-, -910 1 2 0 ; 11, 101; 13,-113; 15, 139; 17, 139; 2,127; 22, 159 antTg1aucoma a g e n t s , 20, 83 a n t i h y p e r l i p i d e m i c s , 2 , 162; 18, 161 antihypertensives, 1, 59; 2, 48; 3 , 53; 47; 5 , 49; 6 , 52; 1, 59; 8 , 52; 2, 57; 1 1 , 61; 3, 60; 13, 71; 1 4 , 61; 2 , 797 73; -
5,
61; 18, 69; 1 9 , 6 1 ; 21, 63;
22,
la,
6 3
a n t i i n f z m m a t o r z s , non-steroidal, 1 , 224; 2 , 217; 3 , 215; 4 , 207; 10, 177; 13, 167; 1 6 , 189 225; 6 , 182; 7 , 208; 8 , 214; 9 , 197; a n t i - i s c h e m i c a g e n t s , 177 71 a n t i m e t a b o l i t e c o n c e p t T d r u g d e s i g n , 11,223
-
c, 5,
366
CUMULATIVE CHAPTER T I T L E S KEYWORD I N D E X , VOL.
-
1-22
antimicrobial drugs c l i n i c a l problems and o p p o r t u n i t i e s , 21, 119 a n t i n e o p l a s t i c s , 2, 166; 3, 150; 4, 154; 5, 144; 129; 128; 2, 139; 10, 131; 118; 12, 120; 13, i20; 14,132; 15, 130; 16, 137; 163; -
2,
1,
8,
z,163; z,137 1%; I , 150; 2, 131; 2, 147; 3, 126; 3 ,
18, 129; 19, 137;
antGarasitiG,
17,
1, 140; 4, 126; 5, 116; 7, 145; 8, 1417 9 , 115; 3, 156; 11, 121;12, 140; 13,-130;
14,72;-15, 1207 16,125; 17, 129; 19, 147 6, 4279, 19 2; 1 ; 3, 1 ; 4, 1 ; 5 , 1 ; 6, 1 ; 7, 6; 8, 1 ; 9, 1 ; 10, 2; 11, 3; 2, 1 ; 13, IT; 14,-12; 3 , 12; 16, - 11; 18, 21; 197 21;
a n t G a r k i n s o z s m drugs, antipsychotics, 1, 1 ;
21, 1 ;
22, 1
a n t i r a d i a t i o n a g e n t s , 1 , 324; 2, 330; 2, 327; 5, 346 a n t i r h e u m a t i c d r u g s , 18, 171 antithrombotics, 7, 7 c 8, 73; 9, 75; 99; 12, 80; 14, 71; 17, 79 1T8; a n t i v i r a l a g e n t s , 1 , 1297 2, 122; 3, 116; 4, 117; 5, 10, 167; 1 1 , 128; 3,-139; 15, 149; 16, 149; 7, 119; 8, 150;-9, 128; -
to,
1m;6,
13,139;ig, ii7;-g, 147
a p o z h i n e c h e m i s t r y , 4, 331 a r a c h i d o n a t e l i p o x y g e n z s e , 16, 21 3 arachidonic acid cascade, 182; 14, 178 a r a c h i d o n i c a c i d m e t a b o l i t e r 17, 203a r t h r i t i s , 13, 167; 16, 189; 175; 171; 201 asymmetric s y n t h e s i s , 13, 282atherosclerosis, 1 , 178; 2, 187; 2, 172; 178; 5, 180; 6, 150;
1 z
v,
3,
11,
4,
169; 8, 183; 15,-162, 3,-161; 11,189 atrial n a t r i u r e t z factor, 21, 273 a u t o r e c e p t o r s , 19, 51 b a c t e r i a l r e s i s t a n c e , 13, 239; 3, 119
1,
bacterial toxins, 12, 2 1 1 basophil d e g r a n u l a t z n , biochemistry, 18, 247 behavior, serotonin, 47 benzodiazepine r e c e p t o r s , 21 b i o i s o s t e r i s m , 2, 283 b i o l o g i c a l f a c t o r s , 2, 39; 1 1 , 42 b i o l o g i c a l membranes, 1 1 , 2 2 2 b i o p h a r m a c e u t i c s , 1,3 3 ; 2, 340; 3 , 337; 302; 5 , 313; 6, 264; 7, 259;
1,
5,
2,
8, 332
b i o g y n t h e s i s , a n t i b i o t i c s , 12, 130 b l o o d - b r a i n b a r r i e r , 20, 305blood enzymes, 1, 2 3 7 b o n e , m e t a b o l i c disease, 12, 223; 15, 228; 17, 261; 22, 169 calcium antagonists/modulaGrs, 17771; g,’;T9; 85 16,257; 18,203 calmodulin a n t a g o n i s t s , SAR, cancer therapy, 2, 166; 3, 1%; 4, 154; 5 , 144; 7, 129; 8, 128; 2, 139;
”,
11,
13, ,120;14,-132; 15; 130; 16, 137; 151; 3, 131; 115;12, 120; 17, 163; 18, 129; 21, 257 c a n z b i n o i d s r 9, 253c a r b o x y l i c acid; m e t a l a t e d , 2, 278 c a r c i n o g e n i c i t y , c h e m i c a l s , 12, 234 c a r d i o t o n i c a g e n t s , 16,93; 5, 92; 2, 71 c a r d i o v a s c u l a r a g e n t s , 2, 6 T c a t a l y s i s , i n t r a m o l e c u l a r , 1,279 c e l l i n v a s i o n , 2, 229 c e l l m e t a b o l i s m , 1,267 c e l l m e t a b o l i s m , c y c l i c AMP, 2, 286 c e l l u l a r r e s p o n s e s , i n f l a m m a t o r y , 12, 152 c h e m o t a x i s , 15, 224; 17, 139; 17, s 3 c h o l e c y s t o k i n z , 18, chronopharmacology, 11,25 1 9,
CUMULATIVE CHAPTER TITLES KEYWORD I N D E X , VOL. 1-22
367 -
11,
c o g n i t i v e d i s o r d e r s , 19, 31; 31 c o l l a g e n a s e s , 1 9 , 231c o l o n y s t i m u l a t i n g f a c t o r , 21, 263 complement i n h i b i t o r s , 15, 193 complement s y s t e m , 7 , 2 X c o n f o r m a t i o n , n u c l e o s i d e , b i o l o g i c a l a c t i v i t y , 5 , 272 conformation, p e p t i d e , b i o l o g i c a l a c t i v i t y , 3 , 2 2 7 c o n g e s t i v e h e a r t f a i l u r e , 22, 85 c o t r a n s m i t t e r s , 0, 51 c y c l i c AMP, 2, 286; 6 , 215; 8 , 224; 1 1 , 291 c y c l i c GMP, 1 1 , 291 c y c l i c n u c l e o t i d e s , 9 , 203; 10, 192; 15, 182 cyt ochrome P-450, 9 ,-290; 19,201 DDT-type i n s e c t i c i d e s , 9 , 3 0 d e r m a t o l o g y and d e r m a t o l o g i c a l a g e n t s , 12, 162; 18, 181; 22, 201 d i a b e t e s , 9, 182; 11, 170; 3, 2,769; 22,213 D i e l s - A l d e r r e a c t i o n , i n t r a m o l e c u l a r , 9 , 270 diuretic, 1, 67; -2 , 59; -3 , 62; -6 , 8 6 83; 10, 71; 1 1 , 71; 61; 15, 100 D N A F s e q u e n c e - s p e c i f i c d r u g s , 2 2 , 259 1 4 , 12; 1 5 , 7 2 ; 1 6 , 1 1 , 103; 18, 21; 0, 4 1 ; 22, 107 dopamine, 13, 1 1 ; d r u g a b u s e , CNS a g e n t s , 9,38 d r u g a l l e r g y , 2, 240 d r u g c a r r i e r s , a n t i b o d i e s , 15, 233 drug carriers, liposomes, 1 q 250 drug d e l i v e r y systems, 1 5 , 3 0 2 ; 275; 305 drug discovery, n a t u r a l s o u r c e s , 301 d r u g d i s p o s i t i o n , 15, 277 d r u g m e t a b o l i s m , 2,227; 4 , 259; 5 , 246; 6 , 205; 8, 234; 9 , 290; 304;-14, - 188; 5, 319; 17, 373 190; 12, 201; 13, 196; e l d e r l y , d r u g a c t i o n i n , 20, 295 electrosynthesis, 30F e n a n t i o s e l e c t i v i t y , drug metabolism, 13, 304 endorphins, 41; 31; 3, 32; 1 c 4 1 ; 1 7 , 21; 18, 51 15, 207e n z y m a t i c monooxygenation r e a c t i o n s , 7 , 249; 9 , 234; f i F 2 4 9 enzyme i n h i b i t o r s , enzyme immunoassay , 18, 285enzymes, b l o o d , 1 , 2'55 enzymes, p r o t e o l y t i c i n h i b i t i o n , 13, 261 enzyme s t r u c t u r e - f u n c t i o n , 22, 293enzymi c s y n t h e s i s , 19, 263e x c i t a t o r y amino a c i G , 22, 31 f e r t i l i t y c o n t r o l , 10,n o ; 1 4 , 168; 21, 169 f o r s k o l i n , 19, 293 free r a d i c a l p a t h o l o g y , 10, 257; 22, 253 GABA, a n t a g o n i s t s , 13, 3 E 41gamete b i o l o g y , f e r t i l i t y c o n t r o l , 10, 240 1 , 99; ,2 9 1 ; 4 , 56; 6 , 68; 8 , 93; 10, 90, gastrointestinal agents, 3,89; 0, 117 1 6 , 83; 1 7 , 89; 12, 91; genetherapy, 8, 2 E g l u c a g o n , mechanism, '8, 193 glucocorticosteroids, 13, 179 g l y c o s y l a t i o n , non-enzymatic, 261 growt h f a c t o r , 11, 159 g r o w t h hormone, 20, 185 h a l l u c i n o g e n s , 1 , 12; 2 , 11; 3 , 1 4 ; 4 , 13; 5 , 23; 6 , 24 15, 8 9 ; c , - 7 1 h e a r t d i s e a s e , ischemic: h e a r t f a i l u r e , 13, 92; 5 7 9 3 ; 22, 85 h e m o r h e o l o g i c agents, 3, 99
159;
S,
2, 17,
9,
0,
11,
3,
12, 13, 3,
s,
2,
368 -
CUMULATIVE CHAPTER TITLES KEYWORD INDEX, VOL. 1-22
h e r b i c i d e s , 2, 311 heterocyclic chemistry, 278 hormones, g l y c o p r o t e i n , 211 hormones, n o n - s t e r o i d a l , 1 , 191; 3 , 184 1 1 , 158; 1 6 , 199 hormones, p e p t i d e , 5 , 210; 7 , 194; 8 , 204; 10, 2 0 2 ; hormones, s t e r o i d , 1 , 213; 208, 3, 207, 199 18, 149 h o s t m o d u l a t i o n , i n f e c t i o n , 8 , 160;-14,46; 5 - h y d r o x y t r y p t a m i n e , 2, 273;-7, 47; 41 hypersensitivity, delayed, 8,-284 h y p e r s e n s i t i v i t y , i m m e d i a t e , 7 , 238; 8, 273 h y p e r t e n s i o n , e t i o l o g y , 9 , 50h y p n o t i c s , 1 , 30; 2, 24;-3, 28; 4 , 28; 7 , 39; 8 , 29; 1 0 , 30; 11, 13; 1 2 , 10; 13, 21; 22;-15, - 227 16, 3 i ; 17, i i ; fi,-ii; ig,Ti; 22, 11 I g E T 18, 2 f i 18, 265 immunity, c e l l u l a r m e d i a t e d , 17, 91; immunoassay, enzyme, 18, 285 immunostimulants, a r t h r i t i s , 2,38; 1 4 , 146 immunosuppressives, a r t h r i t i s , 11 138immunotherapy, cancer, 9, 151 18, 149; 22, 127 immunotherapy , i n f e c t i o u s d i s e a s e s 14,t 14 i n f e c t i o n s , s e x u a l l v t r a n s m i t t e d .' -' i n f l a m m a t i o n , 22, 245 i n h i b i t o r s , complement, 2, 193 i n h i b i t o r s , c o n n e c t i v e t i s s u e , _II, 175 i n h i b i t o r s , enzyme, 13, 249 i n h i b i t o r s , i r r e v e r s i b l e , 9 , 234; 16, 289 i n h i b i t o r s , p l a t e l e t a g g r e g a t i o n , 6 , 60 i n h i b i t o r s , p r o t e o l y t i c enzyme, 13, 261 inhibitors, renin-angiotensin, 82 i n h i b i t o r s , r e v e r s e t r a n s c r i p t i o n , 8 , 251 i n h i b i t o r s , t r a n s i t i o n s t a t e analogs, 7 , 249 inorganic chemistry, medicinal, 8 , 294i n s e c t i c i d e s , 2, 300; 17,311 i n s u l i n , mechanism, 18, 193 i n t e r f e r o n , 8, 150; E,211; 1 6 , 229; 17, 151 interleukin-1, 2 0 , 1 7 z 2, 235i n t e r l e u k i n - 2 , 2 , 191 i n t e r o c e p t i v e d i s c r i m i n a t i v e s t i m u l i , a n i m a l model o f a n x i e t y , 2, 51 intramolecular c a t a l y s i s , 1, 279 i o n o p h o r e s , monocarboxylic a c i d , 3, 246 i r o n c h e l a t i o n t h e r a p y , 13, 219 i s o t o p e s , s t a b l e , 2, 3 1 E 2 , 173 6 - l a c t a m a n t i b i o t i c s , 1 1 , 271; 12, 101; 13, 149; 20, 127,137 B-lactamases, 13, 239;?7, 119 l e a r n i n g , 3 , 2m; 571 l e u k o c y t e m o t i l i t y , 17, 181 l e u k o t r i e n e s , 17,2 9 F 1 9 , 241
2, 12,
z,
z,
2,
I_x
16,
LHRH,
0, 203
l i p i d metabolism, 9 , 172; lo, 182; 1 1 , 180; 12, 191; 13, 184; 1 4 , 198; 15, 162 l i p o s o m e s , 3, 250 lipoxygenase, 16, 213; 1 7 , 203 l y m p h o c y t e s , d e l a y e d h y p e r s e n s i t i v i t y , 8 , 284 m a g n e t i c r e s o n a n c e , d r u g b i n d i n g , 1 1 , 377 market i n t r o d u c t i o n s , 1 9 , 313, 20,?15; 21, 323; 22, 315 mast c e l l degranulationTbiochemGtry, 247 -
lc
mechanism, d r u g a l l e r g y , 3 , 240 mechanisms o f a n t i b i o t i c r e s i s t a n c e , membrane f u n c t i o n , lo, 317
1,217; '3, 239; 17,119
CUMULATIVE C H A P T E R T I T L E S KEYWORD I N D E X , VOL.
1-22
369
membrane r e g u l a t o r s , 11,210 membranes, a c t i v e t r a n s p o r t , 11, 222 memory, 3, 279; 2, 30; 16, 5 1 m e t a b o l i s m , c e l l , 1,2 6 7 y 2 , 286 m e t a b o l i s m , d r u g , 3, 227; 6, 259; 5, 246; 6, 205; 8, 234; 9, 290; 11, 190; 12, 201T 13, 195; 3,354; 14, 788 metabolism, l i p i d , 1 97 ,2; 10, 182; 111 ,80; 12, 191; 14, 198 m e t a b o l i s m , m i n e r a l , 12, 227metal c a r b o n y l s , 8, 3 B metals, d i s e a s e , 2, 321 m i c r o b i a l p r o d u c t s s c r e e n i n g , 11, 149 m i g r a i n e , 2, 41 m i t o g e n i c f a c t o r s , 2, 237 m o l e c u l a r m o d e l i n g , 3, 269 m o n o c l o n a l a n t i b o d i e s , 16, 243 monoxygenases, c y t o c h r o m F P - 4 5 0 , 9 , 290 m u s c l e r e l a x a n t s , 1,30; 2, 24; 2 ; 28; -4, 28; -8, 37 m u s c u l a r d i s o r d e r s , 12, 260 m u t a g e n i c i t y , mutagens, 12, 234 m u t a g e n e s i s , S A R of p r o t e i n s , 18, 237 n a r c o t i c a n t a g o n i s t s , 7, 31; g F 2 0 ; 2, 11; lo, 12; 11, 23; 13, 41 n a t r i u r e t i c a g e n t s , 19; 253 n a t u r a l p r o d u c t s , 6 , 2 7 4 ; 15, 255; 17,301 n a t u r a l k i l l e r c e l l s , 18, x 5 n e o p l a s i a , 8, 160; 1 0 , 1 4 2 n e u r o p e p t i d e s , 21, q; 2, 51 neurotensin, 17731 n e u r o t r a n s m i t t e r s , 3, 264; 4 , 270; 12, 249; 14, 42; 19, 303 n i c o t i n i c a c e t y l c h o l T n e r e c e p t o r , 228,1 ,NMR i n b i o l o g i c a l s y s t e m s , 20, 267NMR i m a g i n g , 20, 277 non-enzymatic g l y c o s y l a t i o n , 14, 261 non-nutritive, sweeteners, x 7 3 2 3 non-steroidal antinflammatories, 1, 224; 2, 217; 3, 215; 4 , 207; 5, 225; 6, 182; 7, 208; 8, 214; 9, 1 9 3 ; - E , 172;s, 167; 16,183 n u c i e i c acid-drug i n t e r a c t i < n s , 13, 316 n u c l e i c a c i d , s e q u e n c i n g , 16, 2 9 F n u c l e i c acid, s y n t h e s i s , 1 s ; 299 n u c l e o s i d e c o n f o r m a t i o n , 5, 272 n u c l e o s i d e s , 1, 299; 2, 304; 3, 297; 5 , 333 n u c l e o t i d e m e t g b o l i s m , 21, 2 4 7 n u c l e o t i d e s , 1, 299; 2 , 7 0 4 ; 3, 297; 5 , 333 n u c l e o t i d e s , c y c l i c , 9 , 203; 70, 192; 15, 182 o b e s i t y , 1,51; 2, 4 4 7 3, 47;-5, 40; 8 7 4 2 ; 11,200; 15, 172; 19, 157 o n c o g e n e s , 18, 275; 21 ,-159,237 o p i o i d r e c e p G r , 1 1 , 3 3 ; 12, 20; 13, 41; 3, 31; 15, 32; '6, 41; 17, 21; 18, 51; 20, 2 1 ; 2 1 , 21 o p i x d s , 1 2 7 2 0 ; 1 6 7 4 1 ; 17, 21; 2, 51; 20, 21; 21, 21 o r g a n o c o p p e r reagents, 327 o s t e o a r t h r i t i s , 22, 179 osteoporosis, z T 1 6 9 p a r a s i t e b i o c h e m i s t r y , 16, 269 p a t e n t s i n m e d i c i n a l c h e m i s t r y , 2, 331 p a t h o p h y s i o l o g y , plasma membrane, 10, 213 p e n i c i l l i n b i n d i n g p r o t e i n s , 18, 1p e p t i c u l c e r , 1, 99; 2, 91; 4 7 5 6 ; 6, 68; 8, 93; 10, 90; 12, 91; 16, 83; 17, 89; 18, 89; 3, 81; g y 93; 2 , 191 peptide conformation, 13, 227
LE
37 0 -
CUMULATIVE C H A P T E R TITLES KEYWORD I N D E X , VOL.
1-22
p e p t i d e hormones, 5 , 210; 7, 194; 8 , 204; 10, 202; 1 1 , 158; 303 7 , 194; 8 , 204; 10,702; 1 6 , 199 p e p t i d e , hypothalamus, p e p t i d e , S A R , 5 , 266 p e p t i d e , s y n t h e s i s , 5 , 307; 7 , 289; 309 peptide, synthetic, 289; 2, 296 p e p t i d e , t h y r o t r o p i n , 17, 31p e r i o d o n t a l d i s e a s e , 1% 228 pharmaceutics, 1 , 3 3 1 72 , 340; 3 , 337; 302; 5 , 313; 254; 264; 7 , 259; 33F p h a r m a c o k i n e t i c s , 3, 227; 3 , 337; 4 , 259; 4 , 302; 5 , 246; 5 , 313; 6 205; 8 , 234; 2, 290; 1 1 , 190;-12, - 2017 1 3 , 195; 13, 354; 1 4 , 788; 14,-309;
2,
16,
1,
2,
i,
1 6 , 319; 17, 333pharmacophorcidentification ,
6,
6,
15 , 267 pharmacophoric p a t t e r n s e a r c h i n g , 299 p h o s p h o l i p a s e s , 1 9 , 213; 22, 223 p h y s i c o c h e m i c a l p a r a m e t e r s , d r u g d e s i g n , 3 , 348; 4 , 314; 5 , 285 p i t u i t a r y hormones, 7 , 194; 8 , 204; 10, 252 plasma membrane p a t h o p h y s i o l o g y , 10 , 2 1 3 plasminogen a c t i v a t o r , 18, 257; 107 p l a t e l e t a c t i v a t i n g fact& ( P A F ) , 243; 20, 193 p l a t e l e t aggregation, 60 p o l y e t h e r a n t i b i o t i c s , 10, 246 polyamine m e t a b o l i s m , l r 253 p o l y m e r i c reagents, 11,281 p r o d r u g s , lo, 306; 2 x 303 p r o l a c t i n s e c r e t i o n , 15, 202 prostacyclin, 178p r o s t a g l a n d i n s , 3, 290; 5 , 170; 6 , 137; 7 , 157; 8 , 172; 9 , 162; 1 1 , 80 p r o t e i n growth f a c t o r s , 219 p r o t e i n a s e s , a r t h r i t i s , 1 4 , 219 protein kinases, 18, 213p r o t e i n k i n a s e C , 20, 227 psoriasis, 12, 1 6 F p s y c h i a t r i c E s o r d e r s , 11 , 42 p s y c h o s e s , b i o l o g i c a l f a x o r s , 2, 39 p s y c h o t o m i m e t i c a g e n t s , 9 , 27 pulmonary a g e n t s , 1 , 92,-2, 83; 3 , 84; 4 , 67; 5 , 55; 7 , 89; 9 , 85; 1 0 , 80; 51; 7 0 ; - 3 , 517 14, 5 i ; 15, 59; 17, 51; 18, 6 1 ; 2 0 , 71; 1_1, 73; 22, 73 q u a n t i t a t i v e S A R , 6 , 245; 8 , 313; 1 1 , 301; 3,292; 281 q u i n o l o n e a n t i b a c t e r i a l s , 2i, 139; 117 radioimmunoassays, 10, 284r a d i o i s o t o p e l a b e l e d d r u g s , 7 , 296 radioimaging agents , 293r a d i o l i g a n d b i n d i n g , 19, 283 receptor binding, 1 2 , 7 4 9 r e c e p t o r mapping, 1 4 , 299; 267 r e c e p t o r , c o n c e p t a Z f u n c t i o n , 21, 211 r e c e p t o r s , a d a p t i v e c h a n g e s , 19,241 r e c e p t o r s , a d r e n e r g i c , 15 , 2 1 T receptors, 6-adrenergic m o c k e r s , 1 4 , 81 1 6 , 21 r e c e p t o r s , benzodiazepine, receptors, cell surface, 127211 r e c e p t o r s , d r u g , 1 , 236; 2, 227, 8, 262 r e c e p t o r s , h i s t a m i n e , 14,-91 r e c e p t o r s , n e u r o t r a n s m i t t e r s , 3, 264 ; 12 , 249 r e c e p t o r s , n e u r o l e p t i c , 1 2 , 249 receptors, opioid, 3xg, 20; 13, 4 1 ; 1 4 , 31; 15, 32; 16, 4 1 ; 17, 21
2,
cc n,
6,
2,
c,
2,
z,
z,
la,
5,
11,
17,
CUMULATIVE C H A P T E R T I T L E S KEYWORD I N D E X , VOL.
1-22
recombinant DNA, 17, 229; 2, 307; 1 9 , 223 r e n a l blood f l o w , 1 6 , 103 r e n i n , 13, 8 2 ; 2 0 , 2 5 7 r e p e r f u s i o n i n j u r y , 22, 253 reproduction, 1, 2 0 5 2, 199; 3, 200; 4 , 189 r e v e r s e t r a n s c r i p t i o n , 8 , 251 rheumatoid a r t h r i t i s , l i , 138; 219; 171; 21, 201 SAR, q u a n t i t a t i v e , 6 , 4 5 ; 8 , 313; 1 1 , 301; 13, 292; 17, 291 s e d a t i v e - h y p n o t i c s , 7 , 39; 8, 29; lr 13; 12,lO; 13,Tl; 1 4 , 22; 15, 22; 1 6 , 31; 17, 1 1 ; 2 7 1 1 ; 1 1 ; E ,1 1 sedatives, 1 , 30; 2 , 24; 3 , 28; 28; 7 , 39; 8 , 29; 10, 30; 11, 13; 12, 10; 3 ; 21; fl, 22; 13, 22; T6, 31; 17, 11; 1 1 ; 20 , 1; 21, 1 1 s e r x o n i n , b e h a v i o r , 2 , 2 7 5 1,47serum l i p o p r o t e i n s , r e & l a t i o n , 12, 184 sexually-transmitted infections, 1 4 , 114 s i l i c o n , i n b i o l o g y and m e d i c i n e , lo, 265 s i c k l e c e l l anemia, 111, 247 s k e l e t a l muscle r e l a x a n t s , 8 , 37 s l o w - r e a c t i n g s u b s t a n c e s , 15, 6 9 ; 1 6 , 213; 17, 203; 17, 291 sodium/calcium e x c h a n g e , s 7 2 15 s o l i d s t a t e o r g a n i c c h e m i s t r y , 20, 287 s o l u t e a c t i v e t r a n s p o r t , 1 1 , 272 s o m a t o s t a t i n , 1 4 , 209; 18,199 SRS, 15, 69; l q 213; _?_;TT 203; 291 steroirhormon;, 1 , 213; 2 , 208; 3 , 207; 4 , 199 s t r o i d o g e n e s i s , a d r e n a l , 2 7 263 s t e r o i d s , 1, 312; 3 , 307;-4,- 281; 5 , 296; 5 , 192; 6, 162; 7 , 182; 8 , 194;
14,
18,
s,
18,
c,
1 1 , 192
s t i m u l a n t s , 1 , 12; 2 , 1 1 ; 3, 1 4 ; 4 , 13; 5, 13; 6 , 15; 7 , 18; 8, 11 2, 109 s t r o k e , p h a r m a c o l o g i c a l approaches; s u b s t a n c e P , 17, 271; 31 s u b s t i t u e n t c o n s t a n t s , 2 , 347 s u i c i d e enzyme i n h i b i t o r s , 16, 289 s u p e r o x i d e d i s m u t a s e s , 10, z 7 superoxide radical, 1 0 , 2 5 7 sweeteners, n o n - n u t r i E v e , 1 7 , 323 s y n t h e s i s , asymmetric , 9, 2 E s y n t h e s i s , computer-assisted, 12, 288; 16, 281; 21, 203 tandem mass s p e c t r o m e t r y , 2, 3 3 t h r o m b o s i s , 5 , 237 thromboxane s y n t h e t a s e , 22, 95 thromboxanes, 1 4 , 178 t h y r o t r o p i n r e l e a s i n g hormone, 2, 31 t o p o i s o m e r a s e , 21, 247 t o x i c i t y r e v e r s a c 15, 233 t o x i c i t y , m a t h e m a t i c a l models, 18, 303 toxicology, comparative, 11, 2 4 2 t o x i n s , b a c t e r i a l , 2, 2 1 F t r a n s c r i p t i o n , r e v e r s e , 8, 251 tumor n e c r o s i s f a c t o r , 227 235 vasoconstrictors, 4, 7 T vasodilators, 77; 2, 49 veterinary drugs, 161 v i r u s e s , 2, 238 v i t a m i n D , 10, 295; 15, 288; 17,261; 1 9 , 179 waking f u n c t G n s , S F 2 1 water, s t r u c t u r e s , 5 , 256 x e n o b i o t i c s , c y c l i c Z u c l e o t i d e m e t a b o l i s m , 2,182 x-ray c r y s t a l l o g r a p h y , 2, 293
18,
4,
16,